Hematologic Cancers

Sorafenib Maintenance Therapy After Allo-HSCT Improves Outcomes in FLT3-ITD–Positive AML

By

Lauren Dembeck, PhD

Publish Date August 4, 2020

Among patients with FLT3-internal tandem repeats, sorafenib maintenance therapy reduces the risk of relapse and death after allo-HSCT.

Identifying Risk Factors for Invasive Fungal Infection in Ibrutinib-Treated CLL Patients

By

Susan Moench, PhD, PA-C

Publish Date July 30, 2020

Ibrutinib-mediated macrophage inhibition may underlie an increased risk of invasive fungal infection in patients with CLL treated with this agent.

MPN Genomic Calculator Performs Well in Real-Life Cohort of Patients With Essential Thrombocythemia

By

Susan Moench, PhD, PA-C

Publish Date July 29, 2020

The MPN Genomic Calculator uses clinical, laboratory, and genomic characteristics of patients with MPN to estimate their clinical outcomes.

Genetic Prognostic Factors in CLL Treated With Novel Compounds

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date July 29, 2020

Obinutuzumab plus venetoclax was associated with improved outcomes compared with obinutuzumab plus chlorambucil, regardless of the presence of unfavorable genetic prognostic factors.

Antithymocyte Globulin to Prevent Graft-vs-Host Disease Following Matched-Sibling Donor Transplantation

By

Vicki Moore, PhD

Publish Date July 29, 2020

For patients receiving HLA-matched sibling donor transplantation, antithymocyte globulin can reduce the incidence of acute graft-vs-host-disease.